Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)

Published:2017-10-27 Issue:1 Volume:10 Page:
ISSN:1757-2215
Container-title:Journal of Ovarian Research
language:en
Short-container-title:J Ovarian Res

Author:

Kischkel Frank Christian,Meyer Carina,Eich Julia,Nassir Mani,Mentze Monika,Braicu Ioana,Kopp-Schneider Annette,Sehouli Jalid

Funder

Bundesministerium für Wirtschaft und Energie (DE)

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynecology,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13048-017-0365-9.pdf

Reference19 articles.

1. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998;25:340–8.

2. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4:87–94.

3. du Bois A, Lück H-J, Meier W, Adams H-P, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.

4. du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group and the Groupe d’Investigateurs Nationaux pour l’Etude des cancers Ovariens. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:1127–35.

5. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036–45.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gynecologic and Breast Cancers: What's New in Chemoresistance and Chemosensitivity Tests?;Current Problems in Cancer;2023-08

2. The Emerging Role of the SLCO1B3 Protein in Cancer Resistance;Protein & Peptide Letters;2019-12-10

3. Biological Insights into Chemotherapy Resistance in Ovarian Cancer;International Journal of Molecular Sciences;2019-04-30

4. Real‑time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin;Oncology Letters;2018-07-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3